FDx Advisors Inc. Reduces Stock Holdings in AstraZeneca PLC $AZN

FDx Advisors Inc. lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 34.0% in the second quarter, Holdings Channel reports. The fund owned 7,537 shares of the company’s stock after selling 3,883 shares during the quarter. FDx Advisors Inc.’s holdings in AstraZeneca were worth $527,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. NewSquare Capital LLC boosted its stake in shares of AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. Larson Financial Group LLC increased its stake in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after buying an additional 289 shares during the period. Richardson Financial Services Inc. lifted its holdings in AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares in the last quarter. Costello Asset Management INC acquired a new position in AstraZeneca in the 1st quarter worth $29,000. Finally, Maseco LLP purchased a new position in AstraZeneca in the 2nd quarter valued at about $34,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the topic of a number of analyst reports. Jefferies Financial Group assumed coverage on AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $84.58 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $262.32 billion, a price-to-earnings ratio of 31.80, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $86.57. The business has a 50 day simple moving average of $81.41 and a 200-day simple moving average of $75.55.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. During the same quarter in the previous year, the company posted $2.08 earnings per share. The firm’s revenue was up 12.0% on a year-over-year basis. As a group, equities research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.